Related references
Note: Only part of the references are listed.An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries
J. Connor Wells et al.
JAMA ONCOLOGY (2021)
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology
Joseph C. Del Paggio et al.
JAMA ONCOLOGY (2021)
Single-Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019
Olli Tenhunen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Association of Industry Sponsorship With Cancer Clinical Trial Accrual
Dario Pasalic et al.
JAMA ONCOLOGY (2020)
The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review
Alice Fabbri et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2018)
Role of industry funders in oncology RCTs published in high-impact journals and its association with trial conclusions and time to publication
F. Liang et al.
ANNALS OF ONCOLOGY (2018)
Impact of industry collaboration on randomised controlled trials in oncology
Anne Linker et al.
EUROPEAN JOURNAL OF CANCER (2017)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Research output and the public health burden of cancer: is there any relationship?
F. M. Patafio et al.
CURRENT ONCOLOGY (2016)
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs
Chul Kim et al.
MAYO CLINIC PROCEEDINGS (2016)
Drugs, cancer and end-of-life care: A case study of pharmaceuticalization?
Courtney Davis
SOCIAL SCIENCE & MEDICINE (2015)
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs
Sham Mailankody et al.
JAMA ONCOLOGY (2015)
Unintended Consequences of Expensive Cancer Therapeutics-The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity The John Conley Lecture
Tito Fojo et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2014)
Oncology Drug Development and Approval of Systemic Anticancer Therapy by the US Food and Drug Administration
Robert E. Martell et al.
ONCOLOGIST (2013)
Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points
A. Kay et al.
ANNALS OF ONCOLOGY (2012)
Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov
Florence T. Bourgeois et al.
PLOS ONE (2012)
Pastel Injustice: The Corporate Use of Pinkwashing for Profit
Amy Lubitow et al.
ENVIRONMENTAL JUSTICE (2011)
Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health Dimensions
John Abraham
SOCIOLOGY-THE JOURNAL OF THE BRITISH SOCIOLOGICAL ASSOCIATION (2010)
Frequency, Nature, Effects, and Correlates of Conflicts of Interest in Published Clinical Cancer Research
Reshma Jagsi et al.
CANCER (2009)
External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer
Christopher M. Booth et al.
BMC CANCER (2007)
Association between pharmaceutical involvement and outcomes in breast cancer clinical trials
Jeffrey Peppercorn et al.
CANCER (2007)
The uncertainty principle and industry-sponsored research
B Djulbegovic et al.
LANCET (2000)
Share Paper
